TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models


Karine Lélu, et al.
Journal of Hepatology, April 2015, Volume 62, Supplement 2, Page S205 – Download the article
Publication